Eltrombopag Added to Standard Immunosuppressive Treatment as Front-Line Therapy for Severe Aplastic Anemia: Long-Term Outcomes of the Phase-3 Randomized Superiority EBMT-SAAWP RACE Study.
Am J HematolJul 19, 2026 (epub)
Antonio M Risitano, Simona Iacobelli, Austin Kulasekararaj et al.
✦ AI-curated · Sources linked
In 30 seconds
The RACE study evaluated the addition of eltrombopag to standard immunosuppressive treatment in 197 treatment-naive patients with severe aplastic anemia. This phase III randomized trial found that the 2-year cumulative incidence of complete response was significantly higher in the eltrombopag group (62.4% vs. 35.3%; p < 0.001), indicating improved treatment outcomes.
Key findings
- 2-year cumulative incidence of complete response was 62.4% in the eltrombopag group vs. 35.3% in the standard treatment group (p < 0.001).
- 2-year disease-free survival was 56% for eltrombopag vs. 37% for standard treatment (adjusted HR = 0.49; p < 0.001).
- 2-year event-free survival was 48% in the eltrombopag group compared to 32% in the standard treatment group (p < 0.001).
- Evolution to clinical paroxysmal nocturnal hemoglobinuria occurred in 8% of the standard treatment group vs. 1% in the eltrombopag group (p = 0.041).
Why it matters
The findings suggest that incorporating eltrombopag into standard immunosuppressive therapy for severe aplastic anemia can significantly enhance treatment response rates and survival outcomes, which may influence clinical decision-making in managing this condition.